v3.0.7
Please consider this website is continuously evolving and still under development
to harmonize automatic data extraction and integrate manual data annotation.
| Column | Value |
|---|---|
| Trial registration number | NCT04872686 |
|
Full text link
Last imported at : May 5, 2021, 11:25 a.m. Source : ClinicalTrials.gov |
|
|
First author
Last imported at : Jan. 21, 2022, noon Source : ClinicalTrials.gov |
|
|
Contact
Last imported at : Jan. 21, 2022, noon Source : ClinicalTrials.gov |
arefin61dmc@gmail.com |
|
Registration date
Last imported at : May 5, 2021, 11:25 a.m. Source : ClinicalTrials.gov |
2021-05-04 |
|
Recruitment status
Last imported at : Jan. 21, 2022, noon Source : ClinicalTrials.gov |
Completed |
|
Study design
Last imported at : May 5, 2021, 11:25 a.m. Source : ClinicalTrials.gov |
RCT |
|
Allocation
Last imported at : May 5, 2021, 11:25 a.m. Source : ClinicalTrials.gov |
Randomized |
|
Design
Last imported at : May 5, 2021, 11:25 a.m. Source : ClinicalTrials.gov |
Parallel |
|
Masking
Last imported at : May 5, 2021, 11:25 a.m. Source : ClinicalTrials.gov |
Blind label |
|
Center
Last imported at : May 5, 2021, 11:25 a.m. Source : ClinicalTrials.gov |
multi-center |
|
Study aim
Last imported at : May 5, 2021, 11:25 a.m. Source : ClinicalTrials.gov |
Treatment |
|
Inclusion criteria
Last imported at : Nov. 16, 2021, 6:30 p.m. Source : ClinicalTrials.gov |
a. moderately ill covid-19 patient and asymptomatic to mild covid-19 patent having multiple comorbidity inclusion criteria hospital admitted patients tested positive covid-19 within 24 hours in the laboratory by rt-pcr. patients with asymptomatic, mild to moderate illness of covid-19. age group 18 year and above. consent of the patients, wish to be included in the study willingly. |
|
Exclusion criteria
Last imported at : Nov. 16, 2021, 6:30 p.m. Source : ClinicalTrials.gov |
patients with critical covid-19 and moderate covid-19 with other complication. patients having thyroid dysfunction, pregnant or lactating mother. it should not be used prior to or after radioiodine scintigraphy or radioiodine treatment of thyroid carcinoma. patients allergic to iodine should be avoided have participated in other clinical study subjects with other severe acute or chronic conditions that may increase the risk of participation in the study and study treatment, or may interfere with interpretation of study results, and judged by the investigator as not suitable for participation in this clinical trial. b. healthy individual inclusion criteria: healthy individual (non covid-19) age -18 years and above (as below18 years lesser concentration of drug may be required). consent of the participants who wish to participate. |
|
Number of arms
Last imported at : May 5, 2021, 11:25 a.m. Source : ClinicalTrials.gov |
4 |
|
Funding
Last imported at : May 5, 2021, 11:25 a.m. Source : ClinicalTrials.gov |
DR. MALA KHAN |
|
Inclusion age min
Last imported at : May 5, 2021, 11:25 a.m. Source : ClinicalTrials.gov |
18 |
|
Inclusion age max
Last imported at : May 5, 2021, 11:25 a.m. Source : ClinicalTrials.gov |
80 |
|
Countries
Last imported at : May 5, 2021, 11:25 a.m. Source : ClinicalTrials.gov |
Bangladesh |
|
Type of patients
Last imported at : May 5, 2021, 11:25 a.m. Source : ClinicalTrials.gov |
Mild/moderate disease at enrollment |
|
Severity scale
Last imported at : May 5, 2021, 11:25 a.m. Source : ClinicalTrials.gov |
2: Mild/moderate disease at enrollment |
|
Total sample size
Last imported at : May 5, 2021, 11:25 a.m. Source : ClinicalTrials.gov |
798 |
|
primary outcome
Last imported at : May 5, 2021, 11:25 a.m. Source : ClinicalTrials.gov |
Effectiveness of 0.6% PVP-I assessment through viral concentration measurement;Viral concentration assessment in Naso-Oropharynx by applying 0.6% PVP-I on COVID-19 positive, moderately ill admitted patient |
|
Notes
Last imported at : May 5, 2021, 11:25 a.m. Source : ClinicalTrials.gov |
None |
|
Phase
Last imported at : May 5, 2021, 11:25 a.m. Source : ClinicalTrials.gov |
Phase 3 |
|
Arms
Last imported at : May 5, 2021, 11:25 a.m. Source : ClinicalTrials.gov |
[{"arm_notes": "moderately ill COVID-19 positive patient ", "treatment_id": 1015, "treatment_name": "Povidone-iodine", "treatment_type": "Mouthwash", "pharmacological_treatment": "Non pharmacological treatment"}, {"arm_notes": "asymptomatic to mild COVID-19 patient having multiple comorbidity ", "treatment_id": 1015, "treatment_name": "Povidone-iodine", "treatment_type": "Mouthwash", "pharmacological_treatment": "Non pharmacological treatment"}, {"arm_notes": "healthy volunteer ", "treatment_id": 1015, "treatment_name": "Povidone-iodine", "treatment_type": "Mouthwash", "pharmacological_treatment": "Non pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}] |